Edward Livant1, Amy Heaps2, Cliff Kelly3, Rashika Maharaj4, Natasha Samsunder5, Lindiwe Nhlangulela6, Patrick Karugaba7, Ravindre Panchia8, Jeanne Marrazzo9, Zvavahera Mike Chirenje10, Urvi M Parikh11. 1. Magee-Womens Research Institute, Pittsburgh, PA, United States. 2. University of Pittsburgh, Pittsburgh, PA, United States. 3. SCHARP, Seattle, WA, United States. 4. South Africa Medical Research Council HIV Prevention Research Unit, Durban, South Africa. 5. CAPRISA, Durban, South Africa. 6. Aurum Institute, Klerksdorp, South Africa. 7. MU-JHU Research Collaboration, Kampala, Uganda. 8. Perinatal HIV Prevention Unit, University of the Witwatersrand, Johannesburg, South Africa. 9. University of Washington, Seattle, WA, United States. 10. UZ-UCSF, Harare, Zimbabwe. 11. University of Pittsburgh, Pittsburgh, PA, United States. Electronic address: ump3@pitt.edu.
Abstract
BACKGROUND: Early and accurate detection of HIV is crucial when using pre-exposure prophylaxis (PrEP) for HIV prevention to avoid PrEP initiation in acutely infected individuals and to minimize the risk of drug resistance in individuals with breakthrough infection. OBJECTIVE: To determine if fourth-generation antigen/antibody (Ag/Ab) rapid diagnostic tests (RDT) would have detected HIV infection earlier than the third-generation RDT used in MTN-003 (VOICE). STUDY DESIGN:5029 VOICE participants were evaluated with third-generation Alere Determine™ HIV-1/2, OraQuick ADVANCE® Rapid HIV-1/2, Uni-Gold™ Recombigen®HIV-1/2 and Bio-Rad GS HIV-1/2+O EIA; and fourth-generation Alere Determine™ HIV-1/2 Ag/Ab Combo, Conformité Européene (CE)-Marked Alere™ HIV Combo and Bio-Rad HIV Combo Ag/Ab EIA. Multispot®, GS HIV-1 Western Blot (WB) and Geenius™ (Bio-Rad) were also evaluated. RESULTS: Of 57 antibody-negative pre-seroconversion plasma samples with HIV RNA >20 copies/mL identified, 16 (28%) were reactive by CE-Marked Alere™ HIV Combo (1 Ab; 9 Ag; 6 Ag/Ab reactive) and 4 (7%) by Alere Determine™ HIV-1/2 Ag/Ab Combo (2 Ab; 2 Ag; 0 Ag/Ab reactive) (p=0.0005). Multispot® confirmed only 1 of 16 acute infections while WB and Geenius™ confirmed none. GS HIV Combo Ag/Ab EIA identified 27 of 57 (47%) pre-seroconversion RNA-positive samples. CONCLUSION: In VOICE, 28% of infections missed by current third-generation RDT would have been identified with the use of CE-Marked Alere™ HIV Combo. Geenius™, Multispot® and WB were all insensitive (<10%) in confirming infections detected by fourth-generation assays. An improved diagnostic algorithm that includes a fourth-generation RDT with HIV RNA testing will be essential for efficiently identifying seroconverters on PrEP.
RCT Entities:
BACKGROUND: Early and accurate detection of HIV is crucial when using pre-exposure prophylaxis (PrEP) for HIV prevention to avoid PrEP initiation in acutely infected individuals and to minimize the risk of drug resistance in individuals with breakthrough infection. OBJECTIVE: To determine if fourth-generation antigen/antibody (Ag/Ab) rapid diagnostic tests (RDT) would have detected HIV infection earlier than the third-generation RDT used in MTN-003 (VOICE). STUDY DESIGN: 5029 VOICE participants were evaluated with third-generation Alere Determine™ HIV-1/2, OraQuick ADVANCE® Rapid HIV-1/2, Uni-Gold™ Recombigen® HIV-1/2 and Bio-Rad GSHIV-1/2+O EIA; and fourth-generation Alere Determine™ HIV-1/2 Ag/Ab Combo, Conformité Européene (CE)-Marked Alere™ HIV Combo and Bio-Rad HIV Combo Ag/Ab EIA. Multispot®, GS HIV-1 Western Blot (WB) and Geenius™ (Bio-Rad) were also evaluated. RESULTS: Of 57 antibody-negative pre-seroconversion plasma samples with HIV RNA >20 copies/mL identified, 16 (28%) were reactive by CE-Marked Alere™ HIV Combo (1 Ab; 9 Ag; 6 Ag/Ab reactive) and 4 (7%) by Alere Determine™ HIV-1/2 Ag/Ab Combo (2 Ab; 2 Ag; 0 Ag/Ab reactive) (p=0.0005). Multispot® confirmed only 1 of 16 acute infections while WB and Geenius™ confirmed none. GS HIV Combo Ag/Ab EIA identified 27 of 57 (47%) pre-seroconversion RNA-positive samples. CONCLUSION: In VOICE, 28% of infections missed by current third-generation RDT would have been identified with the use of CE-Marked Alere™ HIV Combo. Geenius™, Multispot® and WB were all insensitive (<10%) in confirming infections detected by fourth-generation assays. An improved diagnostic algorithm that includes a fourth-generation RDT with HIV RNA testing will be essential for efficiently identifying seroconverters on PrEP.
Authors: Yen T Duong; Yvonne Mavengere; Hetal Patel; Carole Moore; Julius Manjengwa; Dumile Sibandze; Christopher Rasberry; Charmaine Mlambo; Zhi Li; Lynda Emel; Naomi Bock; Jan Moore; Rejoice Nkambule; Jessica Justman; Jason Reed; George Bicego; Dennis L Ellenberger; John N Nkengasong; Bharat S Parekh Journal: J Clin Microbiol Date: 2014-08-13 Impact factor: 5.948
Authors: Nora E Rosenberg; Gift Kamanga; Sam Phiri; Dominic Nsona; Audrey Pettifor; Sarah E Rutstein; Deborah Kamwendo; Irving F Hoffman; Maria Keating; Lillian B Brown; Beatrice Ndalama; Susan A Fiscus; Seth Congdon; Myron S Cohen; William C Miller Journal: J Infect Dis Date: 2011-12-29 Impact factor: 5.226
Authors: Jeanne M Marrazzo; Gita Ramjee; Barbra A Richardson; Kailazarid Gomez; Nyaradzo Mgodi; Gonasagrie Nair; Thesla Palanee; Clemensia Nakabiito; Ariane van der Straten; Lisa Noguchi; Craig W Hendrix; James Y Dai; Shayhana Ganesh; Baningi Mkhize; Marthinette Taljaard; Urvi M Parikh; Jeanna Piper; Benoît Mâsse; Cynthia Grossman; James Rooney; Jill L Schwartz; Heather Watts; Mark A Marzinke; Sharon L Hillier; Ian M McGowan; Z Mike Chirenje Journal: N Engl J Med Date: 2015-02-05 Impact factor: 91.245
Authors: Joanne D Stekler; George Ure; Joshua D O'Neal; Aric Lane; Fred Swanson; Janine Maenza; Claire Stevens; Robert W Coombs; Joan Dragavon; Paul D Swenson; Matthew R Golden Journal: J Clin Virol Date: 2016-01-02 Impact factor: 3.168
Authors: Mars Stone; John Bainbridge; Ana M Sanchez; Sheila M Keating; Andrea Pappas; Wes Rountree; Chris Todd; Sonia Bakkour; Mark Manak; Sheila A Peel; Robert W Coombs; Eric M Ramos; M Kathleen Shriver; Paul Contestable; Sangeetha Vijaysri Nair; David H Wilson; Martin Stengelin; Gary Murphy; Indira Hewlett; Thomas N Denny; Michael P Busch Journal: J Clin Microbiol Date: 2018-07-26 Impact factor: 5.948
Authors: Adedotun A Adetunji; Moses O Adewumi; Obaro S Michael; Samuel A Fayemiwo; Adesola Ogunniyi; Babafemi O Taiwo Journal: Am J Trop Med Hyg Date: 2019-08 Impact factor: 2.345
Authors: Mark M Manak; Linda L Jagodzinski; Ashley Shutt; Jennifer A Malia; Mike Leos; Jason Ouellette; Siriwat Akapirat; Donn L Colby; Nittaya Phanuphak; Leigh Anne Eller; Merlin L Robb; Mark de Souza; Jintanat Ananworanich; Sheila A Peel Journal: J Clin Microbiol Date: 2019-09-24 Impact factor: 5.948
Authors: Susan H Eshleman; Estelle Piwowar-Manning; Mariya V Sivay; Barbara Debevec; Stephanie Veater; Laura McKinstry; Linda-Gail Bekker; Sharon Mannheimer; Robert M Grant; Margaret A Chesney; Thomas J Coates; Beryl A Koblin; Jessica M Fogel Journal: J Clin Virol Date: 2018-01-11 Impact factor: 3.168
Authors: Valentine Wanga; Victor Omollo; Elizabeth A Bukusi; Josephine B Odoyo; Jennifer F Morton; Lara Kidoguchi; Rachel Johnson; James P Hughes; Connie Celum; Jared M Baeten Journal: J Int AIDS Soc Date: 2020-08 Impact factor: 5.396
Authors: Tamara Elliott; Eduard J Sanders; Meg Doherty; Thumbi Ndung'u; Myron Cohen; Pragna Patel; Gus Cairns; Sarah E Rutstein; Jintanat Ananworanich; Colin Brown; Sarah Fidler Journal: J Int AIDS Soc Date: 2019-12 Impact factor: 5.396